The strategy to simultaneously hit these targets in pancreatic cancer was based on (1) the observation that some sigma-2 receptor ligands are effective against pancreatic cancers [3–7] and (2) that cancer cells are sensitive to changes in energy levels because of their increasing energy need [8]. This evidence concerns the gene TMEM97 and familial pancreatic carcinoma.